Key drivers include the rising obesity and type 2 diabetes prevalence, strong pipeline of dual/triple agonists, and increasing adoption of oral GLP-1 drugs for weight management. https://www.datamintelligence.com/research-report/glucagon-like-peptide-1-analogues-market